$PTGX
Protagonist Therapeutics Inc
PRICE
$7.87 ▲2.078%
Last Close
VOLUME
921,505
DAY RANGE
7.56 - 7.92
52 WEEK
7.39 - 50.54
Key Metrics
Market Cap
382.44 M
Beta
1.85
Avg. Volume
1.55 M
Shares Outstanding
48.66 M
Yield
0%
Public Float
0
Next Earnings Date
2022-08-03
Next Dividend Date
Company Information
Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. Rusfertide (PTG-300) is an injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 clinical study for hereditary hemochromatosis. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in a 150 patient Phase 2 study for the potential treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease. Two additional second-generation oral interleukin-23 receptor antagonist candidates PN-235 and PN-232, are in early stages of clinical development. The Company has developed a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms.
Website: www.protagonist-inc.com
HQ: ,
Related News